Please use the links below to search by the first letter of a expert's last name or use the tabs above to browse by health topic, date or sponsor.
Brian Druker, M.D.
Dr. Druker specializes in caring for and treating patients with chronic myelogenous leukemia (CML). In his early medical training, witnessing chemotherapy's effects on patients drove him to find a better way to treat cancer. Starting in the lab, he led the development and clinical trials of the drug Gleevec for CML. Gleevec was the first of its kind – a highly successful daily oral medication to target damaged cells, leave healthy cells alone and cause minimal side effects. Dr. Druker continues to seek even better treatments for his patients, who are his inspiration. In 2009, Dr. Druker was honored with "America's Nobel Prize" in medicine, the Lasker-DeBakey Award for Clinical Medical Research.
As Director of the Knight Cancer Institute, a national leader in translational research, Dr. Druker and his team are focused on making unprecedented advances in cancer research with more than 1,000 research projects under way. More than 200 clinical trials are currently in progress, with the goal of transforming discoveries into new cures, standards of care, treatments and therapies.
He received his medical degree from the University of California San Diego, completed his residency at Barnes Hospital, Washington University, St. Louis and completed his fellowship in Medical Oncology at the Dana-Farber Cancer Institute, Harvard Medical School, Boston.
|Brian Druker: Compassionate Care and Personalized Medicine||Watch Now >>|
|Brian Druker: My Vision for CML and the Road to a Cure||Watch Now >>|